Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Replimune Group, Inc.

REPL Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017โ€“FY2026

Last close ยท Oct 23, 2026

$11.46

4.4%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$314M
Free cash flow Cash from operations minus capital spending.
โˆ’$285M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$1.1B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$3.15 EPS (TTM)

What Replimune Group, Inc. does

No business description yet.

Legal name
Replimune Group, Inc.
Fiscal year ends
March 31, 2026
Latest annual report
10-K ยท Jun 29, 2026
Accession ยท CIK
0001628280-26-045886
0001737953

Revenue and margins

Replimune Group, Inc. had โ€” of revenue in fiscal 2026.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$285M in fiscal 2026, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Replimune Group, Inc. returned โ€” to shareholders in fiscal 2026. The diluted share count rose 15.2%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Replimune Group, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $396M$583M$421M$484M$269M
Debt incl. finance leases $27.0M$55.3M$70.9M$71.9M$108M
Debt / equity 0.0x0.1x0.1x0.1x0.5x
Interest coverage โ€”โˆ’90.2xโˆ’52.2xโˆ’45.3xโˆ’47.1x
Current ratio 19.5x17.5x10.7x8.0x4.8x
Quick ratio 19.5x17.5x10.7x8.0x4.8x
Total assets $461M$647M$488M$551M$332M
Total liabilities $50.0M$91.3M$113M$135M$166M
Shareholders' equity $411M$555M$375M$416M$166M
Net debt (โˆ’ = net cash) โˆ’$369Mโˆ’$528Mโˆ’$350Mโˆ’$412Mโˆ’$161M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โ€” โœ“ โœ• โœ“ โœ• โœ• โœ• โœ• โœ•
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โœ• โœ• โœ“ โœ•
Current ratio rose โ€” โ€” โœ“ โœ“ โœ“ โœ• โœ• โœ• โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
F-score โ€” / 3โ€” / 4โ€” / 6โ€” / 6โ€” / 6โ€” / 61 / 71 / 72 / 71 / 7
Accruals ratio โ€”โˆ’5.7%โˆ’5.0%4.1%โˆ’5.0%โˆ’7.1%โˆ’8.3%โˆ’5.3%โˆ’10.6%โˆ’7.6%
Altman Z'' โ€”โˆ’1.7311.755.2015.3210.177.770.84โˆ’0.42โˆ’13.44

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Research and development $6.9M $13.5M $22.2M $38.8M $56.8M $79.5M $127M $175M $189M $221M
Operating income โˆ’$9.6M โˆ’$19.2M โˆ’$30.9M โˆ’$56.2M โˆ’$80.0M โˆ’$118M โˆ’$177M โˆ’$235M โˆ’$262M โˆ’$320M
Interest expense โ€” โ€” โ€” $0.7M $0.8M $0.0M $2.0M $4.5M $5.8M $6.8M
Pretax income โˆ’$7.7M โˆ’$19.7M โˆ’$30.8M โˆ’$52.6M โˆ’$80.9M โˆ’$118M โˆ’$174M โˆ’$215M โˆ’$247M โˆ’$314M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.3M $0.4M $0.5M โˆ’$0.6M
Net income โˆ’$7.7M โˆ’$19.7M โˆ’$30.8M โˆ’$52.6M โˆ’$80.9M โˆ’$118M โˆ’$174M โˆ’$216M โˆ’$247M โˆ’$314M
Net income to common โˆ’$7.7M โˆ’$19.7M โˆ’$30.8M โˆ’$52.6M โˆ’$80.9M โˆ’$118M โˆ’$174M โˆ’$216M โˆ’$247M โˆ’$314M
Diluted EPS โˆ’$1.55 โˆ’$3.96 โˆ’$1.33 โˆ’$1.54 โˆ’$1.75 โˆ’$2.26 โˆ’$2.99 โˆ’$3.24 โˆ’$3.07 โˆ’$3.38
Diluted shares 0.00B 0.00B 0.02B 0.03B 0.05B 0.05B 0.06B 0.07B 0.08B 0.09B
Cash flow
Cash from operations โˆ’$7.1M โˆ’$16.0M โˆ’$25.4M โˆ’$60.6M โˆ’$61.4M โˆ’$82.2M โˆ’$128M โˆ’$185M โˆ’$192M โˆ’$280M
Capital expenditure $0.2M $0.1M $2.6M $6.5M $2.4M $2.3M $2.3M $5.7M $6.7M $4.2M
Free cash flow โˆ’$7.3M โˆ’$16.2M โˆ’$28.0M โˆ’$67.1M โˆ’$63.8M โˆ’$84.5M โˆ’$130M โˆ’$191M โˆ’$199M โˆ’$285M
Depreciation and amortization $0.1M $0.1M $0.1M $0.5M $1.7M $2.1M $2.4M $2.7M $3.5M $3.3M
Stock-based compensation $0.2M $0.8M $2.7M $7.7M $11.8M $24.3M $28.1M $34.1M $35.0M $32.3M
Balance sheet
Cash and short-term investments $20.7M $61.6M $135M $169M $476M $396M $583M $421M $484M $269M
Total debt โ€” โ€” โ€” $9.8M โ€” $0.0M $28.6M $44.8M $46.4M $83.3M
Finance lease liabilities โ€” โ€” โ€” $27.4M $27.2M $27.0M $26.6M $26.1M $25.5M $24.8M
Current assets โ€” $64.7M $141M $174M $484M $404M $593M $434M $496M $279M
Current liabilities โ€” $5.2M $9.9M $11.9M $14.5M $20.8M $33.8M $40.4M $62.4M $58.2M
Property and equipment, net โ€” $0.4M $12.2M $6.9M $7.4M $7.9M $7.5M $10.5M $13.7M $13.0M
Total assets โ€” $65.2M $154M $234M $543M $461M $647M $488M $551M $332M
Total liabilities โ€” $6.9M $16.5M $50.4M $44.4M $50.0M $91.3M $113M $135M $166M
Shareholders' equity โˆ’$11.5M โˆ’$28.1M $138M $184M $499M $411M $555M $375M $416M $166M
Returns
Return on capital โ€” โ€” โ€” โˆ’177.8% โ€” โˆ’600.2% โˆ’25,251.5% โ€” โ€” โ€”
Return on capital employed โ€” โˆ’32.1% โˆ’21.4% โˆ’25.3% โˆ’15.1% โˆ’26.9% โˆ’28.9% โˆ’52.5% โˆ’53.5% โˆ’116.7%
Return on equity โ€” โ€” โˆ’56.2% โˆ’32.7% โˆ’23.7% โˆ’25.9% โˆ’36.1% โˆ’46.4% โˆ’62.6% โˆ’107.9%
Return on assets โ€” โˆ’30.2% โˆ’28.1% โˆ’27.1% โˆ’20.8% โˆ’23.5% โˆ’31.5% โˆ’38.0% โˆ’47.6% โˆ’71.1%
Return on tangible equity โ€” โ€” โˆ’22.4% โˆ’28.6% โˆ’16.2% โˆ’28.7% โˆ’31.4% โˆ’57.6% โˆ’59.5% โˆ’188.9%
Growth
Share count change โ€” 0.1% 366.0% 47.7% 35.0% 12.9% 11.5% 14.4% 21.0% 15.2%
Financial health
Debt / equity โ€” โ€” โ€” 0.1x โ€” 0.0x 0.1x 0.1x 0.1x 0.5x
Interest coverage โ€” โ€” โ€” โˆ’76.6x โˆ’97.7x โ€” โˆ’90.2x โˆ’52.2x โˆ’45.3x โˆ’47.1x
Current ratio โ€” 12.5x 14.3x 14.7x 33.3x 19.5x 17.5x 10.7x 8.0x 4.8x
Quick ratio โ€” 12.5x 14.3x 14.7x 33.3x 19.5x 17.5x 10.7x 8.0x 4.8x
Quality scores
Piotroski F-score โ€” โ€” โ€” โ€” โ€” โ€” 1.0 1.0 2.0 1.0
Altman Z'' โ€” โˆ’1.7 11.8 5.2 15.3 10.2 7.8 0.8 โˆ’0.4 โˆ’13.4
Accruals ratio โ€” โˆ’5.7% โˆ’5.0% 4.1% โˆ’5.0% โˆ’7.1% โˆ’8.3% โˆ’5.3% โˆ’10.6% โˆ’7.6%

Source: SEC EDGAR XBRL filings (CIK 0001737953). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open